Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study.
Fenlai Tan(Betta Pharmaceuticals (China)), Yan Sun(Dongguan People’s Hospital), Yinxiang Wang(Betta Pharmaceuticals (China)), Jintao He(Sichuan Cancer Hospital), Kewei Ma(Jilin University), Kejing Ying(Sir Run Run Shaw Hospital), Xueke Jia(Baoding People's Hospital), Jiang Wan(Zhejiang Yongning Pharma (China)), Changxuan You(Southern Medical University), Li Zhang(Tianjin Chest Hospital), Changli Wang(Tianjin Medical University Cancer Institute and Hospital), Shucai Zhang(Northeastern University), Aiqin Gu(Nantong University), Lieming Ding(Betta Pharmaceuticals (China)), Junye Wang(Sun Yat-sen University), Haijiao Shen(Zhejiang Yongning Pharma (China)), Yiping Zhang(National Health and Family Planning Commission), Shun Chang Jiao(People's Liberation Army No. 150 Hospital), Meina Wu(Shanxi Medical University)
Cited by 5
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311
Early detection of lung cancer by using an autoantibody panel in Chinese population
|OncoImmunology|2017|203